Literature DB >> 23644380

Major urinary metabolites of 6-keto-prostaglandin F2α in mice.

Dmitry V Kuklev1, Joseph A Hankin, Charis L Uhlson, Yu H Hong, Robert C Murphy, William L Smith.   

Abstract

Western diets are enriched in omega-6 vs. omega-3 fatty acids, and a shift in this balance toward omega-3 fatty acids may have health benefits. There is limited information about the catabolism of 3-series prostaglandins (PG) formed from eicosapentaenoic acid (EPA), a fish oil omega-3 fatty acid that becomes elevated in tissues following fish oil consumption. Quantification of appropriate urinary 3-series PG metabolites could be used for noninvasive measurement of omega-3 fatty acid tone. Here we describe the preparation of tritium- and deuterium-labeled 6-keto-PGF2α and their use in identifying urinary metabolites in mice using LC-MS/MS. The major 6-keto-PGF2α urinary metabolites included dinor-6-keto-PGF2α (~10%) and dinor-13,14-dihydro-6,15-diketo-PGF1α (~10%). These metabolites can arise only from the enzymatic conversion of EPA to the 3-series PGH endoperoxide by cyclooxygenases, then PGI3 by prostacyclin synthase and, finally, nonenzymatic hydrolysis to 6-keto-PGF2α. The 6-keto-PGF derivatives are not formed by free radical mechanisms that generate isoprostanes, and thus, these metabolites provide an unbiased marker for utilization of EPA by cyclooxygenases.

Entities:  

Keywords:  cyclooxygenase; eicosapentaenoic acid; fish oil; prostacyclin

Mesh:

Substances:

Year:  2013        PMID: 23644380      PMCID: PMC3679392          DOI: 10.1194/jlr.M037192

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  39 in total

Review 1.  Human biochemistry of the isoprostane pathway.

Authors:  Ginger L Milne; Huiyong Yin; Jason D Morrow
Journal:  J Biol Chem       Date:  2008-02-19       Impact factor: 5.157

2.  Omega-6 fatty acids and risk for cardiovascular disease: a science advisory from the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention.

Authors:  William S Harris; Dariush Mozaffarian; Eric Rimm; Penny Kris-Etherton; Lawrence L Rudel; Lawrence J Appel; Marguerite M Engler; Mary B Engler; Frank Sacks
Journal:  Circulation       Date:  2009-01-26       Impact factor: 29.690

3.  Asymmetric acetylation of the cyclooxygenase-2 homodimer by aspirin and its effects on the oxygenation of arachidonic, eicosapentaenoic, and docosahexaenoic acids.

Authors:  Narayan P Sharma; Liang Dong; Chong Yuan; Kathleen R Noon; William L Smith
Journal:  Mol Pharmacol       Date:  2010-03-01       Impact factor: 4.436

4.  Isoprostanes.

Authors:  L Jackson Roberts; Ginger L Milne
Journal:  J Lipid Res       Date:  2008-10-28       Impact factor: 5.922

5.  Human pharmacology of naproxen sodium.

Authors:  Marta L Capone; Stefania Tacconelli; Maria G Sciulli; Paola Anzellotti; Luigia Di Francesco; Gabriele Merciaro; Patrizia Di Gregorio; Paola Patrignani
Journal:  J Pharmacol Exp Ther       Date:  2007-05-01       Impact factor: 4.030

6.  Cyclooxygenase Allosterism, Fatty Acid-mediated Cross-talk between Monomers of Cyclooxygenase Homodimers.

Authors:  Chong Yuan; Ranjinder S Sidhu; Dmitry V Kuklev; Yuji Kado; Masayuki Wada; Inseok Song; William L Smith
Journal:  J Biol Chem       Date:  2009-02-12       Impact factor: 5.157

7.  Cyclooxygenase-2-dependent prostacyclin formation and blood pressure homeostasis: targeted exchange of cyclooxygenase isoforms in mice.

Authors:  Ying Yu; Jane Stubbe; Salam Ibrahim; Wen-liang Song; Emer M Smyth; Emer M Symth; Colin D Funk; Garret A FitzGerald
Journal:  Circ Res       Date:  2009-11-25       Impact factor: 17.367

8.  The omega-3 index as a risk factor for coronary heart disease.

Authors:  William S Harris
Journal:  Am J Clin Nutr       Date:  2008-06       Impact factor: 7.045

Review 9.  Intakes of long-chain omega-3 fatty acid associated with reduced risk for death from coronary heart disease in healthy adults.

Authors:  William S Harris; Penny M Kris-Etherton; Kristina A Harris
Journal:  Curr Atheroscler Rep       Date:  2008-12       Impact factor: 5.113

10.  Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products.

Authors:  Masayuki Wada; Cynthia J DeLong; Yu H Hong; Caroline J Rieke; Inseok Song; Ranjinder S Sidhu; Chong Yuan; Mark Warnock; Alvin H Schmaier; Chieko Yokoyama; Emer M Smyth; Stephen J Wilson; Garret A FitzGerald; R Michael Garavito; De Xin Sui; John W Regan; William L Smith
Journal:  J Biol Chem       Date:  2007-05-22       Impact factor: 5.157

View more
  5 in total

Review 1.  Prostaglandin E3 metabolism and cancer.

Authors:  Peiying Yang; Yan Jiang; Susan M Fischer
Journal:  Cancer Lett       Date:  2014-03-18       Impact factor: 8.679

2.  Dietary omega-3 fatty acids modulate the eicosanoid profile in man primarily via the CYP-epoxygenase pathway.

Authors:  Robert Fischer; Anne Konkel; Heidrun Mehling; Katrin Blossey; Andrej Gapelyuk; Niels Wessel; Clemens von Schacky; Ralf Dechend; Dominik N Muller; Michael Rothe; Friedrich C Luft; Karsten Weylandt; Wolf-Hagen Schunck
Journal:  J Lipid Res       Date:  2014-03-16       Impact factor: 5.922

3.  Biomarkers for personalizing omega-3 fatty acid dosing.

Authors:  Yan Jiang; Zora Djuric; Ananda Sen; Jianwei Ren; Dmitry Kuklev; Ian Waters; Lili Zhao; Charis L Uhlson; Yu H Hong; Robert C Murphy; Daniel P Normolle; William L Smith; Dean E Brenner
Journal:  Cancer Prev Res (Phila)       Date:  2014-08-19

4.  A seven-step plan for becoming a moderately rich and famous biochemist.

Authors:  William L Smith
Journal:  J Biol Chem       Date:  2019-02-08       Impact factor: 5.157

5.  Different Fatty Acids Compete with Arachidonic Acid for Binding to the Allosteric or Catalytic Subunits of Cyclooxygenases to Regulate Prostanoid Synthesis.

Authors:  Liang Dong; Hechang Zou; Chong Yuan; Yu H Hong; Dmitry V Kuklev; William L Smith
Journal:  J Biol Chem       Date:  2015-12-23       Impact factor: 5.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.